Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real‐world multicentre cohort

MT Durheim, E Bendstrup, L Carlson, EM Sutinen… - …, 2021 - Wiley Online Library
Background and objective Antifibrotic therapy with nintedanib or pirfenidone slows disease
progression and reduces mortality in patients with idiopathic pulmonary fibrosis (IPF) …
被引用次数：17 相关文章
[PDF] helsinki.fi

[PDF][PDF] Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort

MT Durheim, E Bendstrup, L Carlson, EM Sutinen… - 2021 - helda.helsinki.fi
Background and objective: Antifibrotic therapy with nintedanib or pirfenidone slows disease
progression and reduces mortality in patients with idiopathic pulmonary fibrosis (IPF) …
[PDF] helsinki.fi

[PDF][PDF] Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort

MT Durheim - 2021 - researchportal.helsinki.fi
Background and objective: Antifibrotic therapy with nintedanib or pirfenidone slows disease
progression and reduces mortality in patients with idiopathic pulmonary fibrosis (IPF) …

Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort

MT Durheim, E Bendstrup, L Carlson… - Respirology …, 2021 - pubmed.ncbi.nlm.nih.gov
Background and objective Antifibrotic therapy with nintedanib or pirfenidone slows disease
progression and reduces mortality in patients with idiopathic pulmonary fibrosis (IPF) …
[PDF] core.ac.uk

[PDF][PDF] Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort

MT Durheim, E Bendstrup, L Carlson, EM Sutinen… - 2021 - core.ac.uk
Background and objective: Antifibrotic therapy with nintedanib or pirfenidone slows disease
progression and reduces mortality in patients with idiopathic pulmonary fibrosis (IPF) …

Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort

MT Durheim, E Bendstrup, L Carlson… - … (Carlton South. Print), 2021 - duo.uio.no
Background and objective Antifibrotic therapy with nintedanib or pirfenidone slows disease
progression and reduces mortality in patients with idiopathic pulmonary fibrosis (IPF) …

Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.

MT Durheim, E Bendstrup, L Carlson… - …, 2021 - search.ebscohost.com
Background and objective: Antifibrotic therapy with nintedanib or pirfenidone slows disease
progression and reduces mortality in patients with idiopathic pulmonary fibrosis (IPF) …

Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort

MT Durheim, E Bendstrup, L Carlson, EM Sutinen… - Respirology, 2021 - pure.au.dk
Background and objective: Antifibrotic therapy with nintedanib or pirfenidone slows disease
progression and reduces mortality in patients with idiopathic pulmonary fibrosis (IPF) …

Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.

MT Durheim, E Bendstrup, L Carlson… - Respirology (Carlton …, 2021 - europepmc.org
Methods We included 502 patients enrolled in IPF registries from four Nordic countries.
Linear mixed models were used to assess change in FVC and DLCO over time. Cox …

[引用][C] Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort

MT Durheim, E Bendstrup, L Carlson… - …, 2021 - researchportal.helsinki.fi
Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or
pirfenidone in a real-world multicentre cohort — University of Helsinki Skip to main navigation …